Literature DB >> 14594626

Environmental, occupational, and genetic risk factors for alpha-1 antitrypsin deficiency.

Richard R Sharp1, Frederick de Serres, Lee Newman, Robert A Sandhaus, John W Walsh, Ernie Hood, G Jean Harry.   

Abstract

Alpha-1 antitrypsin (AAT) deficiency is an inherited genetic disorder currently diagnosed in approximately 5,000 people in the United States. Although some individuals with AAT deficiency are asymptomatic, the condition often leads to deterioration of lung function in adults and is associated with emphysema, asthma, chronic obstructive pulmonary disease, and other respiratory diseases. In children, AAT deficiency can result in severe liver disease, including fatal cirrhosis in newborn infants. Although much is known about the clinical pathology of AAT deficiency, researchers are just beginning to characterize environmental, occupational, and genetic modifiers affecting the onset and progression of diseases related to AAT deficiency. On 19 August 2002, a group of basic scientists, clinicians, environmental health researchers, and public interest groups gathered at the National Institute of Environmental Health Sciences in Research Triangle Park, North Carolina, to discuss ongoing research on these topics. The goals of this workshop were to a) assess the present state of knowledge regarding environmental and occupational risk factors contributing to AAT deficiency morbidity and mortality, b) define future research needs in this area, and c) explore collaborative opportunities to advance understanding of risk factors affecting the progression of AAT deficiency-related disease. Participants agreed that new research initiatives in these areas represent an opportunity to benefit both basic science, through enhanced understanding of gene-environment interaction, and the AAT deficiency patient community, through innovative new approaches to disease management and treatment.

Entities:  

Mesh:

Year:  2003        PMID: 14594626      PMCID: PMC1241718          DOI: 10.1289/ehp.6325

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  33 in total

Review 1.  Alpha(1)-antitrypsin deficiency, liver disease and emphysema.

Authors:  Helen Parfrey; Ravi Mahadeva; David A Lomas
Journal:  Int J Biochem Cell Biol       Date:  2003-07       Impact factor: 5.085

2.  Asthma features in severe alpha1-antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry.

Authors:  Edward Eden; Jeffrey Hammel; Farshid N Rouhani; Mark L Brantly; Alan F Barker; A Sonia Buist; Robert J Fallat; James K Stoller; Ronald G Crystal; Gerard M Turino
Journal:  Chest       Date:  2003-03       Impact factor: 9.410

3.  alpha 1-antitrypsin deficiency in early childhood.

Authors:  T Sveger
Journal:  Pediatrics       Date:  1978-07       Impact factor: 7.124

4.  Atopy, asthma, and emphysema in patients with severe alpha-1-antitrypysin deficiency.

Authors:  E Eden; D Mitchell; B Mehlman; H Khouli; M Nejat; M H Grieco; G M Turino
Journal:  Am J Respir Crit Care Med       Date:  1997-07       Impact factor: 21.405

5.  Transfection of nasal mucosa with a normal alpha1-antitrypsin gene in alpha1-antitrypsin-deficient subjects: comparison with protein therapy.

Authors:  K L Brigham; K B Lane; B Meyrick; A A Stecenko; S Strack; D R Cannon; M Caudill; A E Canonico
Journal:  Hum Gene Ther       Date:  2000-05-01       Impact factor: 5.695

6.  Genetic epidemiology of alpha-1 antitrypsin deficiency in southern Europe: France, Italy, Portugal and Spain.

Authors:  F J de Serres; I Blanco; E Fernández-Bustillo
Journal:  Clin Genet       Date:  2003-06       Impact factor: 4.438

7.  Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events.

Authors:  James K Stoller; Robert Fallat; Mark D Schluchter; Ralph G O'Brien; Jason T Connor; Nicholas Gross; Kevin O'Neil; Robert Sandhaus; Ronald G Crystal
Journal:  Chest       Date:  2003-05       Impact factor: 9.410

8.  Feasibility of a clinical trial of augmentation therapy for alpha(1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group.

Authors:  M D Schluchter; J K Stoller; A F Barker; A S Buist; R G Crystal; J F Donohue; R J Fallat; G M Turino; C E Vreim; M C Wu
Journal:  Am J Respir Crit Care Med       Date:  2000-03       Impact factor: 21.405

9.  Mass screening of newborn Swedish infants for alpha antitrypsin deficiency.

Authors:  C B Laurell; T Sveger
Journal:  Am J Hum Genet       Date:  1975-03       Impact factor: 11.025

10.  The liver in adolescents with alpha 1-antitrypsin deficiency.

Authors:  T Sveger; S Eriksson
Journal:  Hepatology       Date:  1995-08       Impact factor: 17.425

View more
  1 in total

1.  Cutoff level to detect heterozygous alpha 1 antitrypsin deficiency in Turkish population.

Authors:  Halis Simsek; Aslı Pinar; Akif Altinbas; Alparslan Alp; Yasemin H Balaban; Yahya Buyukasik; Osman Ozcebe; Gulsen Hascelik; Gokhan Gedikoglu; Gonca Tatar
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.